Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Oct;28(4):389-98.
doi: 10.1080/10550880903183034.

A trial to reduce hepatitis C seroincidence in drug users

Michael D Stein  1 , Debra S Herman, Bradley J Anderson
Affiliations
Randomized Controlled Trial

A trial to reduce hepatitis C seroincidence in drug users

Michael D Stein et al. J Addict Dis. 2009 Oct.

Abstract

To test whether a four-session motivational intervention would reduce hepatitis C virus (HCV) seroincidence among injection and non-injection drug users compared to an assessment-only condition, we performed a randomized 24-month clinical trial. At baseline, 277 participants reported using heroin or cocaine at least three times weekly were HCV antibody negative, 65% were male and 46% were Caucasian and 39% reported having injected drugs. Of the 15 (5.4%) individuals who seroconverted, all reported injecting drugs either at baseline or during follow-up. Seroconversion rates did not differ significantly by treatment assignment (p =.79). The annual HCV incident rate was 8.20 (95% confidence interval [CI] = 4.76-14.13) for injectors and 0.74 (95% CI = 0.19-2.98) for non-injectors per 100 person-years. Significantly fewer participants in the intervention group initiated injection drug use behaviors (p =.009). This intervention was no more effective at reducing HCV seroconversion than assessment alone but did decrease injection initiation.

Trial registration: ClinicalTrials.gov NCT00218192.

PubMed Disclaimer

References

    1. Gerberding JL. Management of occupational exposures to blood-borne viruses. New England Journal of Medicine. 1995;32:444–451. - PubMed
    1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis c virus infection in the United States, 1988 through 1994. New England Journal of Medicine. 1999;341:556–562. - PubMed
    1. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health. 2001;91:42–46. - PMC - PubMed
    1. Howe CJ, Fuller CM, Ompad DC, Galea S, Koblin B, Thomas D, et al. Association of sex, hygiene, and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City. Drug and Alcohol Dependence. 2005;79:389–395. - PubMed
    1. Gyarmathy V, Neaigus A, Miller M, Friedman SR, Des Jarlais DC. Risk correlates of prevalent HIV, hepatitis B virus and hepatitis C virus infections among noninjecting heroin users. Journal of Acquired Immune Deficiency Syndromes. 2002;30:448–456. - PubMed

Publication types

MeSH terms

Substances

Associated data